Over the past two decades, the molecular characterization of metastatic colorectal cancer
(mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As …

Introduction The presence of a BRAF-V600E mutation in metastatic colorectal cancer
(mCRC) is observed in approximately 12% of cases and is associated with poor prognosis …

The BRAFV600E mutation is a well-accepted poor prognostic factor in patients with
metastatic colorectal cancer (mCRC), as it confers Ras-independent stimulation of the …

Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …

The personalization of cancer care is rooted in the premise that there are subsets of patients
with tumors harboring clinically relevant targets for patient-specific treatments. Colorectal …

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-
V600E mutation in their tumors, which is associated with a poor response to standard …

Around 8–12% of patients with advanced colon rectal cancer (CRC) present with BRAF
alterations, in particular V600E mutation, which is associated with right-side, poorly …

Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world.
It is a heterogeneous disease, which can be classified into different subtypes, characterized …

BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this
tumor type on the basis of prognostic and predictive implications. BRAF alterations in …

Background First-line therapeutic strategies for patients with BRAF V600E-mutated (BRAF
mt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized …